ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Results of Operations and Financial ConditionItem 2.02.Results of Operations and Financial Condition.
On November 2, 2017, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2017 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit99.1 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 2.02.Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release, dated November 2, 2017 |
Ultragenyx Pharmaceutical Inc. ExhibitEX-99.1 2 rare-ex991_6.htm EX-99.1 rare-ex991_6.htm Exhibit 99.1 Contact Ultragenyx Pharmaceutical Inc. Investors & Media Danielle Keatley 415-475-6876 Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update NOVATO,…To view the full exhibit click here
About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.
